肾内科

订阅

MedSci主页 / 所有栏目 / 肾内科

JASN：透析患者补充维生素D不能改善贫血症状

2015-12-19 MedSci译 MedSci原创

透析维生素D贫血
关注

根据即将出现在美国肾脏病杂志JASN的一项研究，补充维生素D不能改善血液透析患者的贫血状况。营养维生素D在体内，骨外具有许多功能，维生素D缺乏牵涉到很多疾病，从心血管疾病到癌症。初步证据表明，营养补充维生素D可以通过增加血细胞产生，红细胞生成对透析患者有益。由于许多肾功能不全的患者会发生贫血或红细胞水平较低，补充维生素D将对这些人有益。在这项最大规模的检测维生素D对透析患者的影响的随机临床试验中，

根据即将出现在美国肾脏病杂志JASN的一项研究，补充维生素D不能改善血液透析患者的贫血状况。

营养维生素D在体内，骨外具有许多功能，维生素D缺乏牵涉到很多疾病，从心血管疾病到癌症。初步证据表明，营养补充维生素D可以通过增加血细胞产生，红细胞生成对透析患者有益。由于许多肾功能不全的患者会发生贫血或红细胞水平较低，补充维生素D将对这些人有益。

在这项最大规模的检测维生素D对透析患者的影响的随机临床试验中，医学博士Dana Miskulin（塔夫茨医学中心）和她的同事发现维生素D2补充剂6个月并没有减少透析病人用药物刺激红细胞产生的需要。

“这项研究也没有发现血液透析患者补充营养维生素D对其他几个次级结果包括甲状旁腺激素水平，炎症标志物，感染，或心血管事件的影响，但这些临床结果的统计力量是有限的，”Miskulin博士说。该试验共包括了被随机分配到补充6个月的维生素D2或安慰剂治疗的276例患者。

原始出处：

D. C. Miskulin, K. Majchrzak, H. Tighiouart, R. S. Muther,Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency,JASN,2015.12.18

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=176078, encodeId=e2831e6078c6, content=VD还可以改善贫血, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Feb 14 09:52:31 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941274, encodeId=db8b19412e479, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Jul 06 16:08:00 CST 2016, time=2016-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776803, encodeId=f7a61e7680364, content=<a href='/topic/show?id=5b989244667' target=_blank style='color:#2F92EE;'>#贫血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92446, encryptionId=5b989244667, topicName=贫血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81a339030187, createdName=medscijoin, createdTime=Fri Apr 08 23:08:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48230, encodeId=1d364823005, content=值得看，好好收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570588, encodeId=b9b215e058882, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Mon Dec 21 00:08:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46892, encodeId=26e74689234, content=更长远一点能不能影响？, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Sun Dec 20 20:04:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46797, encodeId=b62046e975d, content=很喜欢这种研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec6488436, createdName=a191008346, createdTime=Sun Dec 20 08:58:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46733, encodeId=159846e332b, content=why？, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Sat Dec 19 13:18:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2017-02-14 1ddf0692m34(暂无匿称)

    VD还可以改善贫血

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=176078, encodeId=e2831e6078c6, content=VD还可以改善贫血, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Feb 14 09:52:31 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941274, encodeId=db8b19412e479, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Jul 06 16:08:00 CST 2016, time=2016-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776803, encodeId=f7a61e7680364, content=<a href='/topic/show?id=5b989244667' target=_blank style='color:#2F92EE;'>#贫血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92446, encryptionId=5b989244667, topicName=贫血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81a339030187, createdName=medscijoin, createdTime=Fri Apr 08 23:08:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48230, encodeId=1d364823005, content=值得看，好好收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570588, encodeId=b9b215e058882, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Mon Dec 21 00:08:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46892, encodeId=26e74689234, content=更长远一点能不能影响？, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Sun Dec 20 20:04:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46797, encodeId=b62046e975d, content=很喜欢这种研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec6488436, createdName=a191008346, createdTime=Sun Dec 20 08:58:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46733, encodeId=159846e332b, content=why？, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Sat Dec 19 13:18:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2016-07-06 chenhongpeng

    #ASN#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=176078, encodeId=e2831e6078c6, content=VD还可以改善贫血, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Feb 14 09:52:31 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941274, encodeId=db8b19412e479, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Jul 06 16:08:00 CST 2016, time=2016-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776803, encodeId=f7a61e7680364, content=<a href='/topic/show?id=5b989244667' target=_blank style='color:#2F92EE;'>#贫血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92446, encryptionId=5b989244667, topicName=贫血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81a339030187, createdName=medscijoin, createdTime=Fri Apr 08 23:08:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48230, encodeId=1d364823005, content=值得看，好好收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570588, encodeId=b9b215e058882, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Mon Dec 21 00:08:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46892, encodeId=26e74689234, content=更长远一点能不能影响？, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Sun Dec 20 20:04:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46797, encodeId=b62046e975d, content=很喜欢这种研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec6488436, createdName=a191008346, createdTime=Sun Dec 20 08:58:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46733, encodeId=159846e332b, content=why？, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Sat Dec 19 13:18:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2016-04-08 medscijoin

    #贫血症#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=176078, encodeId=e2831e6078c6, content=VD还可以改善贫血, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Feb 14 09:52:31 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941274, encodeId=db8b19412e479, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Jul 06 16:08:00 CST 2016, time=2016-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776803, encodeId=f7a61e7680364, content=<a href='/topic/show?id=5b989244667' target=_blank style='color:#2F92EE;'>#贫血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92446, encryptionId=5b989244667, topicName=贫血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81a339030187, createdName=medscijoin, createdTime=Fri Apr 08 23:08:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48230, encodeId=1d364823005, content=值得看，好好收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570588, encodeId=b9b215e058882, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Mon Dec 21 00:08:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46892, encodeId=26e74689234, content=更长远一点能不能影响？, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Sun Dec 20 20:04:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46797, encodeId=b62046e975d, content=很喜欢这种研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec6488436, createdName=a191008346, createdTime=Sun Dec 20 08:58:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46733, encodeId=159846e332b, content=why？, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Sat Dec 19 13:18:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    值得看，好好收藏

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=176078, encodeId=e2831e6078c6, content=VD还可以改善贫血, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Feb 14 09:52:31 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941274, encodeId=db8b19412e479, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Jul 06 16:08:00 CST 2016, time=2016-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776803, encodeId=f7a61e7680364, content=<a href='/topic/show?id=5b989244667' target=_blank style='color:#2F92EE;'>#贫血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92446, encryptionId=5b989244667, topicName=贫血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81a339030187, createdName=medscijoin, createdTime=Fri Apr 08 23:08:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48230, encodeId=1d364823005, content=值得看，好好收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570588, encodeId=b9b215e058882, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Mon Dec 21 00:08:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46892, encodeId=26e74689234, content=更长远一点能不能影响？, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Sun Dec 20 20:04:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46797, encodeId=b62046e975d, content=很喜欢这种研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec6488436, createdName=a191008346, createdTime=Sun Dec 20 08:58:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46733, encodeId=159846e332b, content=why？, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Sat Dec 19 13:18:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2015-12-21 ewsr6

    #透析患者#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=176078, encodeId=e2831e6078c6, content=VD还可以改善贫血, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Feb 14 09:52:31 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941274, encodeId=db8b19412e479, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Jul 06 16:08:00 CST 2016, time=2016-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776803, encodeId=f7a61e7680364, content=<a href='/topic/show?id=5b989244667' target=_blank style='color:#2F92EE;'>#贫血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92446, encryptionId=5b989244667, topicName=贫血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81a339030187, createdName=medscijoin, createdTime=Fri Apr 08 23:08:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48230, encodeId=1d364823005, content=值得看，好好收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570588, encodeId=b9b215e058882, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Mon Dec 21 00:08:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46892, encodeId=26e74689234, content=更长远一点能不能影响？, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Sun Dec 20 20:04:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46797, encodeId=b62046e975d, content=很喜欢这种研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec6488436, createdName=a191008346, createdTime=Sun Dec 20 08:58:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46733, encodeId=159846e332b, content=why？, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Sat Dec 19 13:18:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2015-12-20 三三五五

    更长远一点能不能影响？

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=176078, encodeId=e2831e6078c6, content=VD还可以改善贫血, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Feb 14 09:52:31 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941274, encodeId=db8b19412e479, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Jul 06 16:08:00 CST 2016, time=2016-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776803, encodeId=f7a61e7680364, content=<a href='/topic/show?id=5b989244667' target=_blank style='color:#2F92EE;'>#贫血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92446, encryptionId=5b989244667, topicName=贫血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81a339030187, createdName=medscijoin, createdTime=Fri Apr 08 23:08:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48230, encodeId=1d364823005, content=值得看，好好收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570588, encodeId=b9b215e058882, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Mon Dec 21 00:08:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46892, encodeId=26e74689234, content=更长远一点能不能影响？, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Sun Dec 20 20:04:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46797, encodeId=b62046e975d, content=很喜欢这种研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec6488436, createdName=a191008346, createdTime=Sun Dec 20 08:58:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46733, encodeId=159846e332b, content=why？, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Sat Dec 19 13:18:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2015-12-20 a191008346

    很喜欢这种研究

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=176078, encodeId=e2831e6078c6, content=VD还可以改善贫血, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Tue Feb 14 09:52:31 CST 2017, time=2017-02-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1941274, encodeId=db8b19412e479, content=<a href='/topic/show?id=bd2f28e0e1' target=_blank style='color:#2F92EE;'>#ASN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2870, encryptionId=bd2f28e0e1, topicName=ASN)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1777154, createdName=chenhongpeng, createdTime=Wed Jul 06 16:08:00 CST 2016, time=2016-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1776803, encodeId=f7a61e7680364, content=<a href='/topic/show?id=5b989244667' target=_blank style='color:#2F92EE;'>#贫血症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92446, encryptionId=5b989244667, topicName=贫血症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=81a339030187, createdName=medscijoin, createdTime=Fri Apr 08 23:08:00 CST 2016, time=2016-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48230, encodeId=1d364823005, content=值得看，好好收藏, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 16:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570588, encodeId=b9b215e058882, content=<a href='/topic/show?id=e53d94835a5' target=_blank style='color:#2F92EE;'>#透析患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94835, encryptionId=e53d94835a5, topicName=透析患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4b0915676167, createdName=ewsr6, createdTime=Mon Dec 21 00:08:00 CST 2015, time=2015-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46892, encodeId=26e74689234, content=更长远一点能不能影响？, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=df9e1651052, createdName=三三五五, createdTime=Sun Dec 20 20:04:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46797, encodeId=b62046e975d, content=很喜欢这种研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=95, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec6488436, createdName=a191008346, createdTime=Sun Dec 20 08:58:00 CST 2015, time=2015-12-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=46733, encodeId=159846e332b, content=why？, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=121e1622385, createdName=chenhui888, createdTime=Sat Dec 19 13:18:00 CST 2015, time=2015-12-19, status=1, ipAttribution=)]
    2015-12-19 chenhui888

    why？

    0

相关资讯

Stroke：血液透析患者缺血性卒中的发病率和病死率较高

    终末期肾病（ESRD）需要血液透析治疗，但该治疗方法比正常肾功能增加了10倍脑卒中的风险。来自一般人群的危险因素和管理策略的知识可能并不适用于这些终末期肾病患者。研究人员进行了一项大规模终末期肾病人群的研究来确定脑卒中的风险因素和预后。       从2007年1月1日到2012年12月31日所有接受血液透析的ESRD成年患者参与

JASN：透析患者的心脏骤停风险可能归因于遗传

与普通人群相比,透析患者的心脏骤停率是普通人群的20倍。研究人员考虑到透析患者发生心脏骤停是否与遗传因素有关。研究人员收集了647457例慢性透析的样本，并从中确定了5117对来自同一个家庭的患者。这些患者每一个都有来自相同人群的匹配对照参与者。McNemar测试被用来比较的家族相关和不相关的匹配者对之间心脏骤停的危险。与表型匹配的无关对照相比，没有共同居住过的的基因相关的家庭成员心脏骤停比值比为

BMC Nephrol：亟需在伴抑郁的透析患者开展高质量随机对照研究

接受血液透析患者的抑郁患病率约为20%-40%。因苦于明显的方法学问题，鲜有关于抗抑郁药对透析患者的有效性临床研究。近期有学者在诊断为严重抑郁的透析患者中评估了开展随机对照试验的可行性。相关论文发表于《BMC肾脏病学》(BMC Nephrol)杂志。该项试验是一项2期筛选阶段的随机对照研究。最初筛选出贝克抑郁量表评分为16分及以上的患者，这些患者被精神病学家诊断为严重抑郁，并受邀参与试验。参与试验

CJASN：急性肾衰患者透析能使患者生存获益（倾向匹配分析）

美国学者研究发现，对于血清肌酐有较大程度升高的急性肾损伤（AKI）患者，起始透析与生存率升高相关，相反，对于血清肌酐较低的AKI患者，起始透析与死亡率升高相关。论文4月7日在线发表于《美国肾脏病学会临床杂志》（Clin J Am Soc Nephrol）。 研究纳入严重AKI患者6119例，其中602例接受了透析治疗。研究结果表明，经倾向性评分匹配后，透析与非透析两组患者间的协变量均衡良好，

NDT：降低终末期肾病透析患者感染的风险综述

如何降低终末期肾病（ESRD）透析患者感染的风险一直是肾脏专科和临床科室所关注的问题。英国伦敦皇家医院的Collier S教授等对此作了简短而精辟的综述，并发表在2014年10月的Nephrology Dialysis Transplantation杂志上。 透析患者感染的原因继心血管疾病之后，感染性疾病是导致透析患者死亡的最常见原因。日本透析治疗学会报告称相比日本的总人群死亡率，2008至2

JASN：高透析率β阻滞剂或增透析者死亡风险

β受体阻滞剂一般用于透析患者减少心脏猝死风险。近期加拿大学者进行了相关研究。结果表明，在长期血液透析患者中，与低透析率β受体阻滞剂相比，高透析率β受体阻滞剂可能导致死亡风险显著升高。论文10月30日在线发表于《美国肾脏病学会杂志》(J Am Soc Nephrol)。 此项基于人群的回顾性队列研究共纳入6588例长期接受透析治疗的受试者，其中β阻滞剂高、低透析率组各纳入3294例患者，该